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Anaesthesia and Intensive Care, Vol. 39, No. 4, July 2011 against standards of best clinical practice, to review its analgesic efficacy and parturient safety and satisfaction. As a result of the audit we implemented procedural changes and midwifery training in the competent and safe use of remifentanil PCA. The re-audit was conducted between December 2008 and November 2009 to ascertain the degree of improvement in standards of care. The analgesic method was put on hold for a month during January 2009, while debate between the New Zealand College of Midwives and the Australian and New Zealand College of Anaesthetists was resolved.
A proforma (available on request) was designed to collect relevant data from clinical notes and partograms of consecutive remifentanil PCA users across the audit cycle to measure performance against four standards: 1) remifentanil PCA commenced within 30 minutes of prescription; 2) satisfactory recording of remifentanil-specific observations, as per a PCA protocol; 3) provision of effective labour analgesia and 4) no maternal or foetal side-effects.
The PCA protocol mandated recordings of maternal blood pressure, heart rate, respiratory rate, oxygen saturation and sedation score prior to remifentanil PCA; continuous pulse oximetry and foetal cardiotocography (CTG) for the first 30 minutes after initiation; maternal oxygen saturation and sedation score every 30 minutes thereafter; and continuous pulse oximetry and sedation score for 30 minutes after each dose/lockout change.
Maternal sedation was assessed by midwifery staff according to an adapted four point scale: 0=alert, 1=responds to voice/contraction, 2=responds to gentle touch, 3=responds to pain, 4=unresponsive. Foetal CTG monitoring was continuous for the first 30 minutes of PCA use but then left to the discretion of the midwifery staff. Apgar scores were compared for all consecutive neonates born by vaginal delivery to women receiving no analgesia (control group) and to women who used remifentanil PCA±Entonox.
A questionnaire (available on request) was developed to assess the parturients' experience.
The remifentanil concentration was 50 µg/ml and was prepared by reconstituting the lyophilised drug in 40 ml of 0.9% saline. The initial PCA bolus dose was 0.5 µg/kg (based on the parturients' ideal body or pre-pregnancy weight, whichever was the lower value), with a two minute lockout. The bolus dose could be increased in 0.25 µg/kg increments to a maximum of 1 µg/kg and the lockout time decreased to one minute, if required. We excluded a continuous infusion and set no total dose limit. An ALARIS ® PCA pump (ALARIS Medical UK Ltd, Basingstoke, Hampshire, UK), capable of a bolus delivery over 20 to 40 seconds was used and a bolus limit of 70 µg set to prevent the administration of dangerously high boluses. The protocol required a four hour interval between pethidine administration and commencement of remifentanil PCA. All remifentanil users received 1:1 supervision from either a hospital-employed midwife or a supervised lead maternity carer. Each parturient was informed of the potential benefits and risks, the purely patient-controlled user modality and the 'off label' use of remifentanil, and their informed consent was documented. Within 48 hours of delivery all users were invited to complete the satisfaction questionnaire. Data obtained from the completed questionnaires were correlated with the clinical notes during the data analysis.
RESULTS
The audit cycle included 244 remifentanil PCA users (82% primiparous women) and 153 completed satisfaction questionnaires were obtained. The mean length of labour was 9.6 hours and mean duration of remifentanil PCA 3.6 hours. The PCA bolus dose ranged from 21 to 70 µg (mean 32 µg).
A comparison of both audits against the four standards of care revealed the following.
Standard 1: Commencement of remifentanil PCA within 30 minutes of prescription. In the first audit, 65% of cases with complete documentation met the standard but documentation was often inadequate. The prescription time was not recorded in 27% of cases and the time of PCA commencement was omitted in 12% of cases. On re-audit, 82% of cases achieved the 30 minute standard (median time 20 minutes, range 0 to 150 minutes) and recording of respective times was achieved in 99%.
Standard 2: Recordings of remifentanil-specific observations as per PCA protocol. During the first three months of the first audit, midwifery staff received daily support from the acute pain team and the compliance rate was 70%. Thereafter there was a sharp fall to 10% compliance, leading to the introduction of the following changes over the course of three months: a new double-sided prescription chart (available on request) was designed to provide defined spaces for date/time of prescription, PCA commencement, bolus doses/ lockout times and spaces for any dose/lockout adjustments. The frontsheet included guidelines on management of potential side-effects. The PCA bolus dose options and lockout increments were prescribed together and on the reverse side of the prescription, a flowchart provided guidance on patient selection, indications, process of administration and observations required prior to and during remifentanil PCA. In collaboration with the obstetric and midwifery team a new partogram was designed to provide a unifying document. This amalgamated remifentanil-specific observations (respiratory rate, sedation scores, time of PCA commencement) and therapy comments with the usual maternal and foetal observations as a unified document (the components were scattered throughout the clinical notes during the period of the first audit). Regular midwifery teaching sessions on the safe use of remifentanil PCA reinforced the importance of stringent monitoring and 1:1 supervision of the parturient. These sessions included pre-training reading material and case scenarios, with emphasis on respiratory rate and sedation score monitoring, and a quiz to test understanding.
The re-audit demonstrated 91% compliance with monitoring standards, especially of physiological parameters such as respiratory rate and sedation scores. The more common observations in obstetrics (oxygen saturation and CTG) already had a much better compliance rate in the first audit (Table 1) .
Standard 3: Provision of effective labour analgesia. In both audits, 94% of women rated remifentanil PCA as excellent, very good or good ( Figure 1 ). The satisfaction questionnaire asked parturients whether one push of the PCA demand button was effective in relieving the pain of contraction ('dose was adequate') and whether the analgesic effect lasted for the duration of contraction ('the lockout time was appropriate'). In both audits, 53% of parturients found the starting PCA dose (0.5 µg/kg) and lockout (two minutes) satisfactory, without adjustment. For 23% in the first audit and 28% in the second audit, after appropriate dose and/or lockout changes, remifentanil PCA was fully effective (i.e. one push covered the pain and duration of contraction), increasing the effectiveness of pain relief to 76% and 81%, respectively. In the first audit, 20% of parturients had a PCA bolus dose increase and 5% a lockout reduction compared to the second audit, during which 44% received a bolus increase and 32% a lockout reduction. Despite some improvement in pain relief in the re-audit, the satisfaction scores did not increase. Overall, only four women requested epidural analgesia and five proceeded to caesarean delivery under spinal anaesthesia.
Standard 4: No maternal and foetal side-effects. No side-effects were experienced by 20% of parturients in audit 1 versus 13% in audit 2. The three most common side-effects were drowsiness, pruritus and nausea. Although drowsiness featured commonly (71% and 81% in respective audits), severity was perceived as mild to moderate in most cases and was welcomed by the majority of parturients for relaxation and rest between contractions ( Table 2 ). Some women commented that the degree of nausea experienced was unchanged in comparison to that from labour itself and/or Entonox (76% of women used Entonox prior to remifentanil PCA, with 20% of women combining these in an unrestricted fashion). Four parturients who suffered severe pruritus received ondansetron intravenously with satisfactory symptom relief. The objective sedation assessment revealed mild sedation (response to voice) in 23% and 34% of parturients in audits 1 and 2; and moderate sedation (response to gentle touch) in 0% and 10%, respectively. No-one developed severe sedation (response to pain only) or unresponsiveness; none required naloxone to reverse respiratory depression and only one had her PCA bolus dose reduced to prevent over-sedation. Sixteen percent desaturated briefly to less than 90%, with no apparent association between the degree of sedation and episodes of desaturation. With simple interventions, such as deep breathing and/or nasal oxygen (2 to 3 l/minute), pulse oximeter readings returned to normal. Parturients were encouraged to comment freely on their experience of using the remifentanil pain pump and frequently indicated high satisfaction and the importance placed on choice with regard to type and timing of pain relief. A comparison of the Apgar scores of neonates born vaginally to women receiving no analgesia (control group) with scores of those women using remifentanil PCA found no significant difference (Table 3) . No neonate required resuscitation or naloxone to reverse respiratory depression. Figure 2 shows the uptake of analgesic methods as a percent of live births per month. Exempting the month of the moratorium, the average use of remifentanil PCA was 8.2%, of epidural analgesia 2% and of systemic pethidine 2.2%. Epidural and pethidine use decreased as the use of remifentanil PCA increased and neonatal respiratory depression and resuscitation needs reduced, presumably due to decreased use of pethidine.
DISCUSSION
Consistent with published studies, our audit found that maternal satisfaction with remifentanil PCA was high, with 94% of women reporting that analgesia was excellent, very good or good 1-6 . In the first audit period the PCA bolus doses and lockout times were often not adjusted, leaving some women dissatisfied. The second audit recorded more adjustments and better analgesia, although satisfaction did not increase, with questionnaire results suggesting that this was due to a higher incidence of side-effects, especially drowsiness.
In the re-audit, higher rates of timely PCA commencement were achieved. A few parturients, however, commented on the long time span between consent by the doctor to actual commencement of PCA. Hill et al reported that dissatisfaction with analgesic care is more related to the non-availability of an anaesthetist and poor timing of pain relief, so midwife-managed remifentanil PCA should have an advantage 7 . We hope to further improve parturients' satisfaction by training midwives in the efficient setup and use of the remifentanil PCA.
The percentage of parturients experiencing no side-effects fell from 20% to 13%, while the most frequent side-effect, drowsiness, increased from 11% to 20% as a result of more frequent dose/lockout adjustments in the second audit. Volmanen et al found in a randomised, controlled, double-blinded study comparing epidural with remifentanil analgesia that sedation was an obvious side-effect with remifentanil but nausea was not increased 6 . Drowsiness was very common, but the majority of parturients classed it as mild to moderate and in both audits it was found to provide welcome relaxation and rest between contractions. Several studies comment on the sedative effect of remifentanil PCA and its safety as long as appropriate 1:1 monitoring is in place 3, [8] [9] [10] .
In both audits, 16% of parturients experienced oxygen saturation below 90%, although this improved with deep breathing and supplemental oxygen. Other studies have demonstrated similar reductions in saturation that are transient and easily rectified 2,8 , although Blair et al found similar episodes among women using pethidine PCA 8 . Episodes of maternal desaturation occur during normal labour in the absence of analgesia -for example one study noted desaturation in 34% of women, lasting 30 seconds to 16 minutes per hour in the second stage of labour 11 . Our audit found no unexpected deviations from the norm as regards neonatal Apgar scores or non-reassuring CTG traces, these results being consistent with other literature 4, 10, [12] [13] [14] [15] [16] [17] .
In the first audit, compliance with remifentanilspecific observations fell dramatically once our pain team withdrew daily supervision. About the same time, we stopped using standard opioid PCA prescription and introduced Early Warning Scoring Forms, intended to unify all observations on one chart during the entire admission. Paradoxically, for the next three months observations were scattered between the PCA form, partogram, CTG printout and clinical notes. This prompted the re-design of the partogram to include the remifentanil specific observations and make it more user-friendly. After its introduction, which coincided with the start of second audit, compliance with monitoring improved dramatically.
The positive feedback from parturients encouraged our midwives to take part in further education and training and the antenatal educators to take greater interest in remifentanil PCA, this being added to classes and information leaflets. The learning points and positive results from our completed audit cycle appear to have encouraged other maternity units to introduce remifentanil PCA for labour analgesia.
In summary, this audit cycle highlights how the introduction of a new analgesia modality needs to be considered 'work in progress' and re-evaluated, to achieve good compliance with best standards of care. Consistent with a number of small studies on this subject, we found high satisfaction, good analgesic efficacy and safety.
